Investigating how CD73 affects breast cancer treatment and progression
Targeting posttranslational modifications of CD73 in TNBCs
This study is looking at how a protein called TRIM21 affects an enzyme named CD73, which plays a role in the growth of triple-negative breast cancer, to find new ways to improve treatment for patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11051127 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of CD73, an enzyme that influences both tumor and immune cells, in the progression of triple-negative breast cancer (TNBC). The study aims to explore how the regulation of CD73 by a specific protein, TRIM21, affects cancer growth and response to therapies. By examining the mechanisms behind CD73 accumulation in tumors, the research seeks to identify new therapeutic targets that could improve treatment outcomes for patients with TNBC. The approach includes laboratory experiments and preclinical models to assess the impact of manipulating CD73 levels on tumor behavior and immune response.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with triple-negative breast cancer who may benefit from novel therapeutic approaches.
Not a fit: Patients with non-breast cancers or those who do not have triple-negative breast cancer may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment strategies that enhance the effectiveness of therapies for patients with triple-negative breast cancer.
How similar studies have performed: Previous research has shown promising results in targeting similar pathways in cancer treatment, indicating potential for success in this approach.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Wan, Yong — Emory University
- Study coordinator: Wan, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.